Warfarin π©Έ
Concise reference for warfarin: indications, INR targets, initiation/maintenance dosing, interactions, and safety. Use the embedded tools for dosing and elevated INR/bleeding management.
Overview
- Vitamin K antagonist (VKA). DOACs are preferred for many VTE and non-valvular AF indications; warfarin remains first-line when DOACs are unsuitable (e.g. mechanical heart valves, some hypercoagulable states, or patient preference).
- Narrow therapeutic index: individualise dosing, using a nomogram plus clinical judgement. Always follow local protocols and anticoagulation clinic guidance.
- Dosing tool: UNMH initiation and maintenance nomograms, with doses rounded to Irish tablet strengths.
- Bleeding and reversal tool: Irish practice from the St James's (NCHCD) warfarin reversal guideline, the CUH Octaplex policy, and emed.ie. Follow your hospital haematology protocol.
INR targets (UNMH)
- Most AF / VTE / NVAF indications: target INR 2.5 (range 2.0β3.0).
- Mechanical aortic bileaflet (NSR, normal LA size) or Medtronic Hall: 2.5 (2.0β3.0) plus aspirin 81 mg daily. UNMH also allows 2.5β3.5 for the first 3 months. Confirm aspirin with cardiology.
- Mechanical mitral (bileaflet/tilting disk), caged-ball/disk, Starr-Edwards, or aortic + mitral mechanical: 3.0 (2.5β3.5) plus aspirin 81 mg daily.
- After prosthetic valve thrombosis: aortic 3.5 (3.0β4.0); mitral 4.0 (3.5β4.5), with aspirin if bleeding risk is low.
- On-X aortic valve: 2.5 (2.0β3.0) for the first 3 months, then 1.5β2.0 (plus aspirin) may be considered per FDA labelling when there are no other thromboembolic risks. Confirm with cardiology.
- Bioprosthetic aortic/mitral: 2.5 (2.0β3.0) for 3β6 months if anticoagulated, then aspirin alone unless other indications.
- Triple therapy (VKA + dual antiplatelet): consider targeting INR 2.0β2.5 while on triple therapy and cover with a PPI.
Initiation and monitoring
- Obtain baseline INR and albumin for all new starts. Day 1: 5β7.5 mg standard, or 2.5 mg if warfarin-sensitive (age >75, decompensated CHF, poor nutrition, thyrotoxicosis, liver disease, interacting drugs, malignancy, high bleed risk).
- Days 2β6: check INR daily and dose from the initiation nomogram (see dosing tool). Rules of thumb: if INR rises >0.5, consider reducing the dose; if INR rises β₯1, consider holding one dose.
- Maintenance (β₯1 week): adjust from the maintenance nomogram. Check adherence, illness, drug interactions, and diet before changing dose. At discharge, use the patientβs home tablet strength.
- Once stable and in range: repeat INR within 8 weeks. Recheck sooner after illness, a drug or diet change, or reversal.
Interactions and other factors (UNMH)
- Raise INR (less warfarin needed): amiodarone, azole antifungals, co-trimoxazole (Bactrim), cephalosporins, chemotherapy, diltiazem, doxycycline, fibrates, H2RAs, isoniazid, macrolides, metronidazole, protease inhibitors, quinolones, PPIs, SSRIs, statins, steroids, thyroid replacement.
- Lower INR (more warfarin needed): azathioprine, barbiturates, carbamazepine, nafcillin, primidone, rifamycins.
- Phenytoin: listed by UNMH in both directions. Monitor INR closely when starting or stopping it.
- Bleeding risk without a large INR change: aspirin, clopidogrel, prasugrel, ticagrelor, NSAIDs, UFH/LMWH, fondaparinux.
- Raise INR: low albumin (more free warfarin), poor oral intake, diarrhoea, broad-spectrum antibiotics, decompensated CHF, infection. Lower INR: more vitamin K in the diet, starting tube feeds.
- Stopping tube feeds can raise INR if the dose was increased to overcome binding. TPN effect depends on its vitamin K content.
- Run a drug-interaction check for every warfarin patient when starting or stopping any medicine.
Patient advice and safety
- Missed dose (NHS): take it as soon as remembered. If not remembered until the next day, skip it and take that dayβs dose as usual. Never take 2 doses. Record missed doses and contact the clinic if it happens often.
- Warning signs: unusual bruising or bleeding, black stools, haematuria, severe headache or neurological signs. Seek urgent review.
- Pregnancy (SmPC): contraindicated in the first and third trimesters and within 48 hours postpartum, as warfarin causes congenital malformations and fetal death. Women of child-bearing age need effective contraception. Get urgent specialist advice if pregnancy is planned or suspected.
- Carry an anticoagulant alert card or bracelet and keep an up-to-date medication list.
Warfarin Bleeding & Reversal Tool
For trained clinicians. Always follow local/hospital protocols.
Bleeding Risk Factors
Higher risk when INR >5:
- Age >70
- Previous bleeding complications
- GI ulcers/haemorrhage
- Prior CVA
- Recent surgery
- Uncontrolled blood pressure
- Recent initiation of anticoagulants
Reversal Plan
Additional Information
Raised INR actions and the major bleed definition follow the St James's (NCHCD) warfarin reversal guideline. Vitamin K 5 mg IV for major bleeding follows emed.ie. PCC dosing and INR checks after PCC follow the CUH Octaplex policy (2022). Always use your hospital haematology protocol.
Most overβanticoagulated patients return to therapeutic range within ~3 days of stopping warfarin.
Monitor: repeat INR per above; more often if PCC given (30β60 min, 6 h, then every 4β24 h).
Discuss prosthetic valve cases with cardiology/haematology before vitamin K or full reversal.
Warfarin Dosing Tool
Initiation & maintenance (UNMH nomogram; target INR 2β3 / 2.5β3.5)
Dosing Plan
Based on the UNMH Warfarin Dosing Guideline (initiation Days 1β6 and maintenance β₯1 week), with doses rounded to Irish tablet strengths. Guidance only: individualise to the clinical scenario and follow local anticoagulation clinic policy.
At discharge, use the patient's home tablet strength; if it changes, counsel them and update pharmacy records. Before adjusting maintenance dose, check adherence, illness, drug interactions, and diet.
Based on
External resources
Educational reference only. Medical disclaimer